A compassionate program assessing ITIL-168 for patients with stage IV cutaneous melanoma
Latest Information Update: 21 Sep 2021
At a glance
- Drugs ITIL-168 (Primary)
- Indications Malignant melanoma
- Focus Expanded access; Therapeutic Use
- Sponsors Instil Bio
- 16 Sep 2021 Results presented in an Instil Bio Media Release.
- 16 Sep 2021 According to an Instil Bio media release, data presented at the 2021 European Society for Medical Oncology (ESMO) Congress.
- 13 May 2021 According to an Instil Bio media release, clinical data from a compassionate use program for the treatment of metastatic melanoma was presented as a late-breaking e-Poster at the AACR (2021).